NASDAQ:HSIC - Henry Schein Stock Price, Price Target & More

Henry Schein trades on the NASDAQ under the ticker symbol "HSIC."

Henry Schein shares split on the morning of Friday, September 15th 2017. The 2-1 split was announced on Wednesday, August 16th 2017. The newly issued shares were distributed to shareholders after the market closes on Thursday, September 14th 2017. An investor that had 100 shares of Henry Schein stock prior to the split would have 200 shares after the split.

Henry Schein declared that its board has authorized a share repurchase plan on Tuesday, September 19th 2017, which authorizes the company to repurchase $400,000,000.00 in shares, according to EventVestor. This repurchase authorization authorizes the company to buy up to 6.3% of its stock through open market purchases. Stock repurchase plans are usually an indication that the company's board of directors believes its shares are undervalued.

Henry Schein, Inc. (NASDAQ:HSIC) issued its earnings results on Tuesday, May, 8th. The company reported $0.95 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.92 by $0.03. The business had revenue of $3.22 billion for the quarter, compared to analyst estimates of $3.18 billion. Henry Schein had a return on equity of 19.68% and a net margin of 3.18%. The firm's revenue for the quarter was up 10.2% compared to the same quarter last year. During the same period last year, the business earned $0.88 earnings per share. View Henry Schein's Earnings History.

Henry Schein updated its FY18 earnings guidance on Tuesday, May, 8th. The company provided EPS guidance of $4.03-4.14 for the period, compared to the Thomson Reuters consensus estimate of $4.09.

19 equities research analysts have issued twelve-month price objectives for Henry Schein's shares. Their forecasts range from $73.00 to $102.00. On average, they anticipate Henry Schein's stock price to reach $81.50 in the next twelve months. This suggests a possible upside of 8.9% from the stock's current price. View Analyst Ratings for Henry Schein.

19 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Henry Schein in the last year. There are currently 1 sell rating, 9 hold ratings and 9 buy ratings for the stock, resulting in a consensus recommendation of "Hold."

Some companies that are related to Henry Schein include Boston Scientific (BSX), Vertex Pharmaceuticals (VRTX), Express Scripts (ESRX), Illumina (ILMN), Humana (HUM), FRESENIUS SE &/S (FSNUY), Zoetis (ZTS), BEXIMCO PHARMAC/S GDR REGS (BXP), Baxter International (BAX), Regeneron Pharmaceuticals (REGN), HCA Healthcare (HCA), Takeda Pharmaceutical (TKPYY), ESSILOR Intl S/S (ESLOY), ASTELLAS PHARMA/ADR (ALPMY) and Edwards Lifesciences (EW).

Media coverage about HSIC stock has trended somewhat positive recently, according to Accern Sentiment. The research firm identifies positive and negative news coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Henry Schein earned a daily sentiment score of 0.05 on Accern's scale. They also gave news stories about the company an impact score of 43.00 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the near term.

Henry Schein's stock is owned by many different of institutional and retail investors. Top institutional shareholders include Swedbank (1.33%), Fenimore Asset Management Inc. (0.36%), Riverbridge Partners LLC (0.27%), Port Capital LLC (0.14%), Fisher Asset Management LLC (0.07%) and Xact Kapitalforvaltning AB (0.04%). Company insiders that own Henry Schein stock include Barry J Alperin, Donald J Kabat, Gerald A Benjamin, James A Harding, Kurt P Kuehn, Lorelei Mcglynn, Mark E Mlotek, Michael Racioppi, Michael S Ettinger, Paul Brons, Paul Rose, Philip A Laskawy and Steven Paladino. View Institutional Ownership Trends for Henry Schein.

HSIC stock was sold by a variety of institutional investors in the last quarter, including Fisher Asset Management LLC, Swedbank, Neville Rodie & Shaw Inc., Riverbridge Partners LLC, Gateway Investment Advisers LLC, Laurel Grove Capital LLC and Montrusco Bolton Investments Inc.. Company insiders that have sold Henry Schein company stock in the last year include Barry J Alperin, Mark E Mlotek, Paul Brons and Paul Rose. View Insider Buying and Selling for Henry Schein.

HSIC stock was acquired by a variety of institutional investors in the last quarter, including Addenda Capital Inc., Xact Kapitalforvaltning AB, Port Capital LLC, Addenda Capital Inc., State of Alaska Department of Revenue, DnB Asset Management AS, IFM Investors Pty Ltd and Fenimore Asset Management Inc.. View Insider Buying and Selling for Henry Schein.

Shares of HSIC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of HSIC stock can currently be purchased for approximately $74.86.

Henry Schein has a market capitalization of $11.53 billion and generates $12.46 billion in revenue each year. The company earns $406.29 million in net income (profit) each year or $3.60 on an earnings per share basis. Henry Schein employs 22,000 workers across the globe.

Henry Schein's mailing address is 135 DURYEA RD, MELVILLE NY, 11747. The company can be reached via phone at 631-843-5500 or via email at [email protected]